N@N

AMGN, ALNY, AGEN, AFFY, AFFX, AEZS, Biomed - Genetics Stocks 9.61% undervalued

^{Published on 2011-01-26 12:43:10 - WOPRAI}
 

January 26, 2011 / M2 PRESSWIRE / BUYINS.NET / http://www.squeezetrigger.com is monitoring the Biomed - Genetics sector and these stocks are the most undervalued as of today. AMGEN INC (NASDAQ:AMGN), ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY), ANTIGENICS INC (NASDAQ:AGEN), AFFYMAX INC (NASDAQ:AFFY), AFFYMETRIX INC (NASDAQ:AFFX), AETERNA ZENTARIS INC (NASDAQ:AEZS) are all expected to go Up as they are undervalued according to industry standard valuation metrics. The valuation model employs a three-factor approach to stock valuation using fundamental variables--the company's trailing 12-month Earnings-Per-Share (EPS), the analyst consensus estimate of the company's forecasted 12-month EPS, and the 30-year Treasury yield--to create a highly accurate reflection of a company's fair value.

The chart below displays the projected Fair Value and Valuation discount/premium of the most undervalued stocks in the highlighted industry group:

     Symbol     Company Name                        Last Close     Fair Value     Valuation                   Industry               
     AMGN       AMGEN INC                           57.16          63.24          9.61% undervalued           Biomed - Genetics      
     ALNY       ALNYLAM PHARMACEUTICALS INC         10.965         11.59          5.35% undervalued           Biomed - Genetics      
     AGEN       ANTIGENICS INC                      0.9495         2.23           57.36% undervalued          Biomed - Genetics      
     AFFY       AFFYMAX INC                         6.91           15.97          56.73% undervalued          Biomed - Genetics      
     AFFX       AFFYMETRIX INC                      4.99           13.06          61.79% undervalued          Biomed - Genetics      
     AEZS       AETERNA ZENTARIS INC                1.5899         2.77           42.64% undervalued          Biomed - Genetics      

Here are some of the variables that are utilized when calculating the Fair Market Valuation of a stock: Long-run EPS growth rate, Duration of Business-growth-cycle, Volatility of EPS growth rate, Systematic or beta risk of the firm, Correlation between the firm's EPS and the interest rate environment, EPS growth volatility, Dividend payout ratio, Buffer earnings, Interest rate related criteria: Interest rate (30 year yield) long-run level, Duration of interest rate cycle, Interest rate volatility. The Fair Market Valuation uses 12-month historic and forecasted EPS values and the current 30-year treasury yield as primary determinants. When calculating risk/return values such as the Sharpe ratio, the historic periods used are five years.

Some expected results of the Valuation Model are: the valuation of a stock increases in a declining interest rate environment. Increasing current and/or projected EPS will produce a higher Valuation. While long-term EPS growth would produce a corresponding long-term Valuation increase, concomitant long-term interest rate increases would offset EPS growth and depress the Valuation. The shorter a company's own business cycle, the higher its stock Valuation will be.

AMGEN INC (NASDAQ:AMGN) - Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and delivers human therapeutics based on advances in cellular and molecular biology primarily in the United States, Europe, and Canada. The company markets primarily recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN, which selectively stimulate the production of neutrophils, a type of white blood cell that helps the body fight infections; and Enbrel, an inhibitor of tumor necrosis factor that plays a role in the bodys response to inflammatory diseases. The company also markets other products, including Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a human monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, its lead product in mid-to-late stage development include Denosumab, a human monoclonal antibody that targets a ligand, known as RANKL, an essential regulator of osteoclasts, which is under regulatory review. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. The company has various collaborative arrangements with Pfizer Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Daiichi Sankyo Company, Limited; Array BioPharma Inc.; Kyowa Hakko Kirin Co. Ltd.; and Cytokinetics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) - Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics based on RNA interference (RNAi). Its lead RNAi therapeutic program includes ALN-RSV01, which is in Phase II clinical trial for the treatment of human respiratory syncytial virus (RSV) infection. The companys product pipeline also comprises ALN-VSP, a Phase I clinical trial product to treat liver cancers. Its products under development stage include ALN-RSV02 for the treatment of RSV infection; ALN TTR01 and ALN TTR02 to treat TTR-Mediated Amyloidosis; ALN-PCS for the treatment of PCSK9/Hypercholesterolemia; and ALN-HTT to treat Huntingtons disease. It has license and collaboration agreements with Roche to develop and commercialize therapeutic products that function through RNAi; and Takeda for the development and commercialization of RNAi therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

ANTIGENICS INC (NASDAQ:AGEN) - Antigenics Inc., a biotechnology company, develops and commercializes technologies to treat cancers and infectious diseases primarily based on immunological approaches. The companys product includes Oncophage, a patient-specific therapeutic cancer vaccine tested in Phase III clinical trials for the treatment of renal cell carcinoma and metastatic melanoma, as well as in Phase II clinical trial for the treatment of glioma. Its product candidate portfolio also includes QS-21 Stimulon adjuvant, which is in Phase III third-party clinical trials for various diseases, including hepatitis, human immunodeficiency virus, influenza, cancer, Alzheimers disease, malaria, and tuberculosis; AG-707, a therapeutic vaccine program tested in a Phase I clinical trial for the treatment of genital herpes; and Aroplatin, a liposomal chemotherapeutic tested in a Phase I clinical trial for the treatment of solid malignancies and B-cell lymphomas. The company was formerly known as Antigenics L.L.C. and changed its name to Antigenics Inc. in February 2000. Antigenics Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

AFFYMAX INC (NASDAQ:AFFY) - Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. The company is developing Hematide, which is in Phase III clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells. Affymax, Inc. has strategic alliance agreements with Takeda Pharmaceutical Company Limited and Nektar Therapeutics AL, Corporation to manufacture, develop, and commercialize Hematide. The company was founded in 2001 and is based in Palo Alto, California.

AFFYMETRIX INC (NASDAQ:AFFX) - Affymetrix, Inc. engages in the development, manufacture, sale, and servicing of consumables and systems for genetic analysis in the life sciences and clinical healthcare markets. The company offers integrated GeneChip microarray platform that includes disposable DNA probe arrays (chips) consisting of nucleic acid sequences, certain reagents for use with the probe arrays, a scanner and other instruments used to process the probe arrays, and software to analyze and manage genomic or genetic information obtained from the probe arrays. Its products are used in various applications, including genotyping and gene expression. The company sells its products directly to pharmaceutical, biotechnology, agrichemical, diagnostics, and consumer products companies; academic research centers; government research laboratories; private foundation laboratories; and clinical reference laboratories in North America and Europe, as well as through life science supply specialists acting as authorized distributors in Latin America, India, the Middle East, and the Asia Pacific regions, including the Peoples Republic of China. It has collaboration partnerships with Beckman Coulter, Inc.; CapitalBio Corporation; Life Technologies, Inc.; Genisphere LLC; and Qiagen GmbH. The company has operations in the United States, Europe, and Japan. Affymetrix, Inc. was founded in 1991 and is headquartered in Santa Clara, California.

AETERNA ZENTARIS INC (NASDAQ:AEZS) - terna Zentaris Inc. operates as a late-stage drug development company specialized in oncology and endocrinology. Its lead oncology compounds include perifosine, an orally active PI3K/Akt pathway inhibitor that is in Phase III registration trial for multiple myeloma; and AEZS-108, a doxorubicin-targeted conjugate in Phase II for the treatment of advanced ovarian and endometrial cancer. The companys lead endocrinology compound, AEZS-130, is an oral ghrelin antagonist in Phase III trial as a diagnostic test for Adult Growth Hormone Deficiency. Its pipeline also includes earlier-stage compounds, such as AEZS-112 that is in a Phase I trial in advanced solid tumors and lymphoma, as well as AEZS-120, an anti-cancer vaccine in pre-clinical development. The company was founded in 1991 and is headquartered in Quebec City, Canada.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net